Does Blue Cross Blue Shield of North Carolina Cover Cialis?

How BCBSNC Formulary Placement Works for Tadalafil

Most Blue Cross Blue Shield of North Carolina plans organize prescription drugs into tiers that determine your copay or coinsurance. Generic tadalafil, available since 2018 after Eli Lilly's patent arrangement with generic manufacturers, sits on Tier 2 or Tier 3 for the majority of BCBSNC commercial plans. Brand-name Cialis is typically excluded entirely or placed on a non-preferred brand tier with substantially higher cost-sharing.

Your specific formulary depends on whether you carry an employer-sponsored plan, an individual ACA marketplace plan (Blue Local, Blue Select, Blue Home), or a Medicare Advantage product. BCBSNC publishes formulary search tools on its member portal where you can enter "tadalafil" and confirm tier placement for your exact plan ID. The formulary updates quarterly, so coverage status can shift at renewal.

A 2022 analysis published in the Journal of Sexual Medicine found that among commercially insured men with erectile dysfunction diagnoses, approximately 72% had at least one PDE5 inhibitor available on formulary, though access varied significantly by plan type and state [1]. North Carolina mirrors this national pattern. BCBSNC tends to favor generic PDE5 inhibitors because their acquisition cost dropped below $1 per tablet after multiple generic entrants gained FDA approval in 2018.

Prior Authorization Requirements

BCBSNC requires prior authorization for tadalafil prescribed for erectile dysfunction on most plan types. This means your prescribing clinician must submit clinical documentation before the pharmacy will process the claim.

The typical approval criteria include a confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x), documentation that the condition is not solely psychogenic without organic contribution, and evidence that no absolute contraindications exist (concurrent nitrate therapy, for example). The American Urological Association's 2018 guideline on erectile dysfunction recommends PDE5 inhibitors as first-line pharmacotherapy for most men with ED, and insurers including BCBSNC reference this guideline when establishing medical necessity criteria [2].

Prior authorization decisions typically arrive within 72 hours for standard requests or 24 hours for urgent requests. If denied, your clinician receives a denial letter citing the specific criterion not met, and you have the right to appeal through BCBSNC's internal review process and, if necessary, through the North Carolina Department of Insurance external review program.

Step Therapy and Quantity Limits

Many BCBSNC plans enforce step therapy protocols requiring members to try sildenafil (generic Viagra) before gaining approval for tadalafil. The rationale is cost-based. Generic sildenafil costs plans approximately $0.50 to $2.00 per tablet at wholesale, compared with $2.00 to $8.00 for generic tadalafil depending on strength and quantity.

If sildenafil produced inadequate results, caused intolerable side effects, or is clinically inappropriate (for instance, a patient who needs the longer 36-hour activity window of tadalafil for spontaneity concerns, or a man with concurrent benign prostatic hyperplasia symptoms), your prescriber can request a step therapy exception. The Endocrine Society's clinical practice guideline on testosterone therapy notes that PDE5 inhibitor selection should account for patient preference, onset of action, and duration of effect [3].

Quantity limits are nearly universal. Standard restrictions allow:

• As-needed tadalafil 10 mg or 20 mg: 6 tablets per 30 days (some plans allow up to 12)
• Daily tadalafil 2.5 mg or 5 mg: 30 tablets per 30 days
• Tadalafil for BPH (5 mg daily): 30 tablets per 30 days, often with a separate BPH diagnosis required

These limits align with the FDA-approved prescribing information, which recommends a maximum frequency of once daily for as-needed dosing [4].

Coverage Differences: Commercial vs. Medicare Advantage vs. ACA Plans

Coverage varies dramatically by product line. This distinction matters because BCBSNC serves over 4.3 million members across North Carolina in various plan categories.

Commercial employer-sponsored plans offer the broadest ED drug coverage. Employers select benefit designs, and many include PDE5 inhibitors with standard prior authorization and quantity limits. Some self-funded employers exclude ED medications entirely as a benefit carve-out. Check your Summary of Benefits and Coverage (SBC) document or call the number on your member ID card.

ACA marketplace plans (Blue Local, Blue Select, Blue Value) must cover Essential Health Benefits, but ED medications are not classified as an Essential Health Benefit under North Carolina's benchmark plan. Coverage inclusion is optional. Many ACA individual plans exclude erectile dysfunction drugs or cover them only with onerous prior authorization.

Medicare Advantage (Blue Medicare HMO/PPO): Since 2006, Medicare Part D has explicitly excluded drugs "used for the treatment of sexual or erectile dysfunction" per Section 1860D-2(e)(2)(A) of the Social Security Act. This exclusion applies to BCBSNC's Medicare Advantage Part D formularies. However, if tadalafil is prescribed exclusively for benign prostatic hyperplasia (BPH) using the diagnosis code N40.1, some Medicare Advantage plans cover daily 5 mg tadalafil under medical necessity. The CMS Medicare Part D formulary guidance explicitly permits coverage of tadalafil 5 mg when the sole indication is BPH [5].

The BPH Coverage Pathway

Tadalafil 5 mg daily received FDA approval for benign prostatic hyperplasia in 2011, creating a coverage pathway that bypasses ED exclusions on many plans. The key trial data demonstrated a 22% to 37% improvement in International Prostate Symptom Score (IPSS) with tadalafil 5 mg daily versus placebo over 12 weeks (N=1,500 across pooled studies) [6].

For BCBSNC members on Medicare Advantage or plans that exclude ED drugs, obtaining coverage for daily tadalafil 5 mg requires:

1. A documented BPH diagnosis (confirmed by IPSS score, digital rectal exam, or imaging)
2. Prescriber attestation that the indication is BPH, not erectile dysfunction
3. Prior authorization submission citing the BPH-specific clinical data

This approach is legitimate when patients genuinely have BPH symptoms. Many men over 50 present with both conditions. A prescriber can appropriately document BPH as the primary indication when clinical evidence supports it. The AUA guideline on lower urinary tract symptoms lists tadalafil 5 mg as an evidence-based treatment option for BPH/LUTS [7].

What You Will Pay Out of Pocket

Assuming coverage approval, your cost depends on your plan's cost-sharing structure. Representative ranges for BCBSNC members in 2025-2026:

• Tier 2 generic (tadalafil): $10 to $35 copay per fill, or 20% to 30% coinsurance
• Tier 3 preferred brand: $50 to $75 copay (rarely applies since brand Cialis is usually excluded)
• Tier 4 non-preferred/specialty: $100+ copay or 30% to 50% coinsurance
• No coverage (plan exclusion or Medicare Part D ED exclusion): full retail price, typically $30 to $400+ per month depending on pharmacy and quantity

Without insurance, GoodRx pricing for generic tadalafil 20 mg (30 tablets) at North Carolina pharmacies ranges from approximately $15 to $90. Costco, Walmart, and Mark Cuban's Cost Plus Drugs consistently offer tadalafil at the lower end of this range.

For brand-name Cialis specifically, Eli Lilly discontinued its patient savings card program after patent expiry, and retail prices exceed $400 for 30 tablets. There is no clinical advantage to brand Cialis over generic tadalafil. The FDA requires bioequivalence testing demonstrating that generics deliver the same active ingredient at the same rate and extent of absorption [8].

How to Check Your Specific BCBSNC Coverage

Rather than relying on general guidance, verify your exact coverage through these steps:

1. Log into the BCBSNC member portal at the website printed on your insurance card
2. Manage to "Find a Drug" or "Formulary Search" and enter "tadalafil"
3. Review tier, prior authorization, step therapy, and quantity limit indicators for your plan
4. Call Member Services (number on card back) and ask: "Is tadalafil covered on my plan for erectile dysfunction, and what prior authorization criteria apply?"
5. Request a Coverage Determination in writing if verbal confirmation is insufficient

Your prescriber's office can also run a real-time eligibility check through their pharmacy benefits verification system, which returns coverage status, copay estimates, and prior authorization requirements within seconds.

Appeal Options When Coverage Is Denied

Denials happen frequently for ED medications. A 2020 retrospective in Urology found that initial prior authorization denial rates for PDE5 inhibitors exceeded 30% across major commercial insurers, though approximately 60% of appeals resulted in overturn [9]. BCBSNC offers a three-level appeal process:

Level 1: Internal review. Submit within 180 days of denial. Include clinical notes, relevant guidelines, and a letter of medical necessity from the prescriber. Response within 30 days (72 hours if expedited).

Level 2: Second-level internal review. If Level 1 is upheld, request escalation. A physician reviewer not involved in the original decision evaluates the case.

Level 3: External review. North Carolina law (N.C.G.S. § 58-50-75 through 58-50-95) grants insured individuals the right to an independent external review by a certified Independent Review Organization (IRO). File through the NC Department of Insurance. The IRO decision is binding on BCBSNC.

Include supporting literature in appeals. The AUA guideline's recommendation of PDE5 inhibitors as first-line therapy [2], documentation of failed alternatives, and any relevant comorbidities (diabetes, cardiovascular disease, post-prostatectomy status) strengthen the case.

Alternatives If BCBSNC Denies Coverage

If your plan excludes tadalafil for ED or your appeal is unsuccessful, several options remain.

Generic sildenafil may be covered at a lower tier with fewer restrictions. It provides equivalent efficacy for many men, with the main difference being a shorter duration of action (4 to 6 hours versus up to 36 hours for tadalafil). The landmark trial by Goldstein et al. established PDE5 inhibitor efficacy for ED with 69% of attempts resulting in successful intercourse versus 22% for placebo [10].

Telehealth platforms (including HealthRX) offer tadalafil prescriptions with transparent pricing that often undercuts insurance copays. Many men find that cash-pay generic tadalafil at $1 to $3 per tablet through these services costs less than their insurance copay would have been.

Manufacturer and pharmacy discount programs at major chains provide tadalafil at reduced rates. Walmart's $4 generic list does not include tadalafil, but their pharmacy discount program still beats many retail prices.

Compounding pharmacies can prepare tadalafil in custom dosages (for example, sublingual troches or lower-strength tablets for daily use) that may cost less than commercial products, though insurance never covers compounded medications.

Tadalafil for Pulmonary Arterial Hypertension: A Different Coverage Track

Tadalafil marketed as Adcirca (40 mg daily) for pulmonary arterial hypertension (PAH) follows a completely separate coverage pathway with specialty pharmacy requirements, no quantity limits typical of ED coverage, and prior authorization criteria based on right heart catheterization data and WHO functional class. The PHIRST trial demonstrated a 33-meter improvement in 6-minute walk distance with tadalafil 40 mg versus placebo in PAH patients (N=405) [11]. If your cardiologist or pulmonologist prescribes Adcirca for PAH, the ED-related restrictions described in this article do not apply.

North Carolina Regulatory Context

North Carolina does not mandate ED drug coverage in its state insurance regulations, unlike a small number of states that require specific medication categories. The NC Department of Insurance oversees plan compliance with the Affordable Care Act's Essential Health Benefits for individual and small group markets, but ED medications fall outside those mandated categories.

However, North Carolina's mental health parity laws (N.C.G.S. § 58-3-220) may apply in limited situations where erectile dysfunction results from a covered mental health condition's treatment (such as SSRI-induced sexual dysfunction). If an antidepressant prescribed for major depressive disorder causes ED, the argument exists that treating the medication's side effect falls under mental health parity requirements. This argument has not been broadly tested in NC courts but represents a potential avenue for denied claims.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has stated: "Erectile dysfunction is a medical condition with well-established organic etiologies including vascular, neurogenic, and hormonal causes. Treating it as a lifestyle concern rather than a medical condition is inconsistent with decades of clinical evidence" [12]. This perspective supports medical necessity arguments in coverage appeals.

The AUA's 2018 position statement reinforces this: "PDE5 inhibitors should be offered as first-line therapy to men with erectile dysfunction who have no contraindications to their use" [2].